LXRX vs. XERS
LXRX (Lexicon Pharmaceuticals, Inc.) and XERS (Xeris Biopharma Holdings, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, LXRX returned -11.46%/yr vs 16.00%/yr for XERS. At a 0.29 correlation, their price movements are largely independent.
Performance
LXRX vs. XERS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LXRX achieves a 93.04% return, which is significantly higher than XERS's 6.24% return.
LXRX
- 1D
- -1.33%
- 1M
- 15.63%
- 6M
- 89.74%
- YTD
- 93.04%
- 1Y
- 105.56%
- 3Y*
- -1.60%
- 5Y*
- -11.46%
- 10Y*
- -17.31%
XERS
- 1D
- -3.25%
- 1M
- 22.83%
- 6M
- 5.17%
- YTD
- 6.24%
- 1Y
- 63.21%
- 3Y*
- 51.05%
- 5Y*
- 16.00%
- 10Y*
- —
LXRX vs. XERS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
LXRX Lexicon Pharmaceuticals, Inc. | 93.04% | 55.72% | -51.73% | -19.90% | -51.52% | 15.20% | -17.59% | -37.50% | -51.50% |
XERS Xeris Biopharma Holdings, Inc. | 6.24% | 131.56% | 44.26% | 76.69% | -54.61% | -40.45% | -30.21% | -58.53% | 7.94% |
Correlation
The correlation between LXRX and XERS is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.33 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Jun 21, 2018 | 0.29 |
The correlation between LXRX and XERS shifts across timeframes, from 0.19 (1 year) to 0.34 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
LXRX:
$986.12M
XERS:
$1.44B
LXRX:
-$0.07
XERS:
$0.07
LXRX:
11.98
XERS:
4.73
LXRX:
4.38
XERS:
113.86
LXRX:
$69.64M
XERS:
$314.85M
LXRX:
$69.00M
XERS:
$187.04M
LXRX:
-$20.38M
XERS:
$41.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LXRX vs. XERS — Risk / Return Rank
LXRX
XERS
LXRX vs. XERS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Xeris Biopharma Holdings, Inc. (XERS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LXRX | XERS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.15 | ||
| Sortino ratioReturn per unit of downside risk | +0.33 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.23 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 2.85 | 1.26 | +1.59 |
| Martin ratioReturn relative to average drawdown | 5.98 | 2.17 | +3.81 |
Loading charts...
Drawdowns
LXRX vs. XERS - Drawdown Comparison
The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum XERS drawdown of -96.22%. Use the drawdown chart below to compare losses from any high point for LXRX and XERS.
Loading charts...
Drawdown Indicators
| LXRX | XERS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -96.22% | -3.69% |
Max Drawdown (1Y)Largest decline over 1 year | -34.09% | -46.57% | +12.48% |
Max Drawdown (3Y)Largest decline over 3 years | -91.83% | -47.20% | -44.63% |
Max Drawdown (5Y)Largest decline over 5 years | -95.25% | -71.63% | -23.62% |
Max Drawdown (10Y)Largest decline over 10 years | -98.48% | — | — |
Current DrawdownCurrent decline from peak | -99.33% | -69.37% | -29.96% |
Average DrawdownAverage peak-to-trough decline | -93.29% | -78.94% | -14.35% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.19% | 26.92% | -10.73% |
Volatility
LXRX vs. XERS - Volatility Comparison
Lexicon Pharmaceuticals, Inc. (LXRX) has a higher volatility of 18.64% compared to Xeris Biopharma Holdings, Inc. (XERS) at 11.32%. This indicates that LXRX's price experiences larger fluctuations and is considered to be riskier than XERS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LXRX | XERS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.64% | 11.32% | +7.32% |
Volatility (6M)Calculated over the trailing 6-month period | 59.84% | 32.65% | +27.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 80.22% | 55.24% | +24.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 97.91% | 67.96% | +29.95% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 97.33% | 79.45% | +17.88% |
Dividends
LXRX vs. XERS - Dividend Comparison
Neither LXRX nor XERS has paid dividends to shareholders.
Financials
LXRX vs. XERS - Financials Comparison
This section allows you to compare key financial metrics between Lexicon Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LXRX vs. XERS - Profitability Comparison
LXRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Lexicon Pharmaceuticals, Inc. reported a gross profit of 20.99M and revenue of 21.10M. Therefore, the gross margin over that period was 99.5%.
XERS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Xeris Biopharma Holdings, Inc. reported a gross profit of 0.00 and revenue of 83.13M. Therefore, the gross margin over that period was 0.0%.
LXRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Lexicon Pharmaceuticals, Inc. reported an operating income of -996.00K and revenue of 21.10M, resulting in an operating margin of -4.7%.
XERS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Xeris Biopharma Holdings, Inc. reported an operating income of 7.92M and revenue of 83.13M, resulting in an operating margin of 9.5%.
LXRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Lexicon Pharmaceuticals, Inc. reported a net income of -1.04M and revenue of 21.10M, resulting in a net margin of -4.9%.
XERS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Xeris Biopharma Holdings, Inc. reported a net income of 2.23M and revenue of 83.13M, resulting in a net margin of 2.7%.
Frequently Asked Questions
LXRX and XERS have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LXRX has higher volatility (18.64%) compared to XERS (11.32%). In terms of maximum drawdown, LXRX dropped -99.91% vs XERS's -96.22%.
LXRX currently has the higher Sharpe Ratio (1.21 vs 1.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LXRX and XERS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer